MGD013 is a first-in-class bispecific tetravalent DART molecule designed to bind PD-1 and LAG-3 and restore function of exhausted T cells. Results from a phase 1 study of MGD013 have shown an acceptable safety profile and early activity in patients with advanced solid tumors and hematologic malignancies.

Results of the study were presented by Jason J. Luke, MD, of University of Pittsburgh Hillman Cancer Center in Pennsylvania, during the ASCO20 Virtual Scientific Program.

The study enrolled 50 patients into a dose escalation study from 1 mg to 1200 mg every 2 weeks, and 157 patients into a cohort expansion study at the phase 2 dose of 600 mg.

About 70% of patients experienced a treatment-related adverse event, with 23.2% experiencing grade 3 or worse events. The most commonly reported adverse events were fatigue (19%) and nausea (11%).

Among the patients in the dose escalation cohort who were evaluable for response there were 3 confirmed partial responses. One occurred in a patient with triple-negative breast cancer, 1 in a patient with mesothelioma, and 1 in a patient with gastric cancer. Eighteen patients had stable disease. This resulted in a disease control rate of 48.8%.

Dr Luke note that several cohorts in the study are ongoing, including a lymphoma cohort. He highlighted 1 patient from that cohort, a 27-year-old man with diffuse large B-cell lymphoma who had progression of disease after CAR-T cell therapy. This patient was given a single dose of MGD013 at 600 mg.

A pretreatment biopsy from the patients lymph node showed high expression of PD-1 and LAG-3. After CAR-T, the patient had CD19 loss. After his dose of MGD013, the patient was admitted to the hospital on day 11 due to grade 2 cytokine release syndrome, but had a complete response on PET scan at day 24. The patient later had allogeneic stem cell transplant and is now in remission 11 months post-MGD103.

Evaluation of MGD103 as monotherapy and in combination with FC-engineered monoclonal antibodies such as margetuximab is going, Dr Luke concluded.

Read more of Cancer Therapy Advisors coverage of the ASCO 2020 meeting by visiting the conference page.

Reference

Luke JJ, Patel MR, Hamilton EP, et al. A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecular binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms. Presented at: ASCO20 Virtual Scientific Program.J Clin Oncol. 2020;38(suppl):abstr 8001.

Continued here:
Bispecific DART Molecule Targeting PD-1, LAG3 Active, Well-Tolerated - Cancer Therapy Advisor

The Canine Stem Cell Therapy Market research report enhanced worldwide Coronavirus COVID19 impact analysis on the market size (Value, Production and Consumption), splits the breakdown (Data Status 2014-2020 and 6 Year Forecast From 2020 to 2026), by region, manufacturers, type and End User/application. This Canine Stem Cell Therapy market report covers the worldwide top manufacturers like (VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet) which including information such as: Capacity, Production, Price, Sales, Revenue, Shipment, Gross, Gross Profit, Import, Export, Interview Record, Business Distribution etc., these data help the consumer know about the Canine Stem Cell Therapy market competitors better. It covers Regional Segment Analysis, Type, Application, Major Manufactures, Canine Stem Cell Therapy Industry Chain Analysis, Competitive Insights and Macroeconomic Analysis.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures)of Canine Stem Cell Therapy[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2081893

Canine Stem Cell Therapy Market report offers comprehensive assessment of 1) Executive Summary, 2) Market Overview, 3) Key Market Trends, 4) Key Success Factors, 5) Canine Stem Cell Therapy Market Demand/Consumption (Value or Size in US$ Mn) Analysis, 6) Canine Stem Cell Therapy Market Background, 7) Canine Stem Cell Therapy industry Analysis & Forecast 20202026 by Type, Application and Region, 8) Canine Stem Cell Therapy Market Structure Analysis, 9) Competition Landscape, 10) Company Share and Company Profiles, 11) Assumptions and Acronyms and, 12) Research Methodology etc.

Scope of Canine Stem Cell Therapy Market:The non-invasive stem cell obtaining procedure, augmented possibility of accomplishing high quality cells, and lower price of therapy coupled with high success rate of positive outcomes have collectively made allogeneic stem cell therapy a preference for veterinary physicians. Moreover, allogeneic stem cell therapy is 100% safe, which further supports its demand on a global level. Pet owners are identified to prefer allogeneic stem cell therapy over autologous therapy, attributed to its relatively lower costs and comparative ease of the entire procedure.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry.

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

Veterinary Hospitals Veterinary Clinics Veterinary Research Institutes

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Allogeneic Stem Cells Autologous Stem cells

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2081893

Geographically, the report includes the research on production, consumption, revenue, Canine Stem Cell Therapy market share and growth rate, and forecast (2020-2026) of the following regions:

Important Canine Stem Cell Therapy Market Data Available In This Report:

Strategic Recommendations, Forecast Growth Areasof the Canine Stem Cell Therapy Market.

Challengesfor the New Entrants,TrendsMarketDrivers.

Emerging Opportunities,Competitive Landscape,Revenue Shareof Main Manufacturers.

This Report Discusses the Canine Stem Cell Therapy MarketSummary; MarketScopeGives A BriefOutlineof theCanine Stem Cell Therapy Market.

Key Performing Regions (APAC, EMEA, Americas) Along With Their Major Countries Are Detailed In This Report.

Company Profiles, Product Analysis,Marketing Strategies, Emerging Market Segments and Comprehensive Analysis of Canine Stem Cell Therapy Market.

Canine Stem Cell Therapy Market ShareYear-Over-Year Growthof Key Players in Promising Regions.

What is the (North America, South America, Europe, Africa, Middle East, Asia, China, Japan)production, production value, consumption, consumption value, import and exportof Canine Stem Cell Therapy market?

To Get Discount of Canine Stem Cell Therapy Market:https://www.researchmoz.us/enquiry.php?type=D&repid=2081893

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

View post:
Coronavirus threat to global Good Growth Opportunities in Canine Stem Cell Therapy Market - Cole of Duty

For millions of Americans, though, keeping normalcy at bay for such a long time is a luxury they cant afford. People need to hold onto their jobs. Or find new ones. The streets are filling up with Americans who are responding to one national crisisthat of police brutality and systemic racismin the midst of another. And the economy is in cardiac arrest.

Just last week, to address this, the governor of my state announced an accelerated reopening. In the last weeks, there were about 1,500 new coronavirus cases in our region, an increase of 37 percent. In all these headlines, I can see cracks in the walls Ive built around my mom and my partner. How do we bubble people stay safe as the world moves ahead? In some ways people who are immunocompromised have lived their lives in preparation for all of this, Mamjunder told me.

Not long ago, in response to WIRED's Covid-19 coverage, the publication got an email from a woman named Brandy Stephens whod been diagnosed with acute lymphoblastic leukemia in 2014, when she was 26. She and her husband had a 1-year-old daughter. Her treatment put her in the hospital for 165 days, 35 of them on a ventilator. During that time a mere houseplant could have killed me, she wrote. I had multi-organ failure, my bone marrow died, I had pulmonary embolisms, a partially collapsed lung. Then, a stem cell transplant built her a new immune system. In July 2019, at the five-year mark, Stephens was finally able to be reimmunized, against the scary things that babies are immunized for.

Most of the world does not know we exist, she wrote.

I called her to ask about how she did it. I needed to know how to shepherd my mom and partner through a reopened world. I couldn't eat takeout for a year post-transplant. I carry sanitizer, gloves, masks, Lysol with me. She added, My husband is my rock. It has become second nature to have real quirks, to, say, go to family gatherings but not get close to anyone. She knows how to do this. I feel for people who never have had to isolate before, she added, I went through that struggle. (Immunocompromised people have figured out how to protest too.)

We are lucky to live in an area that has kept the overall coronavirus numbers low, yet the steady tick of reminders about potential Covid-19 resurgences haunt me. For everyone in this pandemic, its hard right now to accurately see a future beyond quarantine. Will we return to normal this year? What does normal mean? Something different for all of us, of course.

Last Friday afternoon I was working at Moms house, and I took a break. We were sitting in her living room, on her lovely blue couches. The dog tucked his head under her arm. Mom asked me what I was looking forward to.

The question jolted me. In pre-corona times, I tried to keep things on the calendar to look forward to. But over the past two months I have shut that instinct down.

Now, my mind ricocheted. Restaurants. Could I look forward to eating at our favorite pizza joint? My partners brother: He just added a new floor at the top of the house, a big glorious room with sliding glass doors that open to a porch overlooking the Pacific. He wants to have parties in that big, cheerful space. Will we be there?

Here are the things I hope to put on my calendar someday soon: dinner at our friends house. Driving with Mom for a day at our favorite beach, without worrying about crowds. Those parties at my partners brothers house, in that big, cheerful space. And if need be, flights to a different city if the new treatments we need for my partners cancer arrive, via a trial, somewhere else.

I hope I can put all of those things on the calendar, for the time we have left together.

More From WIRED on Covid-19

Read the original post:
The Country Is Reopening. Im Still on Lockdown - WIRED

Health care stakeholders need to invest in value-based care, innovative care delivery models, advanced digital technologies. XploreMR will help you to know declarative, procedural, contextual, and somatic information about the Canine Stem Cell Therapy Market. It also provides a critical assessment of the performance of emerging and mature markets in a new publication titled Global Market Study on Canine Stem Cell Therapy: Ongoing Clinical Trials and Focus on Advancements to Push Adoption in Veterinary Clinics.

A synopsis of the global canine stem cell therapy market with reference to the global healthcare pharmaceutical industry

Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.

Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) and many more Information:https://www.xploremr.com/connectus/sample/2360

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.

Parent Indicators Healthcare

Research Methodology

XploreMR utilizes a triangulation methodology that is primarily based on experimental techniques such as patient-level data, to obtain precise market estimations and insights on Molecule and Drug Classes, API Formulations and preferred modes of administration. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.

Secondary research is used at the initial phase to identify the age specific disease epidemiology, diagnosis rate and treatment pattern, as per disease indications. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, nursing managers, clinical specialists who provide valuable insights on trends and clinical application of the drugs, key treatment patterns, adoption rate, and compliance rate.

Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level.

On the other hand, we also analyse various companies annual reports, investor presentations, SEC filings, 10k reports and press release operating in this market segment to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at Tier level based on their revenues, product portfolio and presence.

Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as per capita healthcare expenditure, disposable income, industry based demand driving factors impacting the market and its forecast trends apart from disease related factors.

Get Full Access Of This Exclusive Report Right Now: https://www.xploremr.com/cart/2360/SL

Standard Report Structure

Target Audience

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type:

Application:

End User:

Region:

Read more:
Canine Stem Cell Therapy Market to Expand with Significant CAGR - WorldsTrend

Many people have found much success with Pet Stem Cell Therapy, and this form of regenerative therapy can be applied to your beloved dogs as well. Stem cell treatments maximize the animals natural healing capabilities, provides relief, and promote overall quality of life. It may be quite the expense, but they have some benefits which cannot be replicated by traditional medicine.

Stem cells are blank slates. They are uncharacterized and unspecialized cells that can grow and divide into many types, like muscle, blood, or organ cells. Stem cells serve as a repair mechanism, removing and replacing problematic cells and tissues by turning into the needed cells and reproducing.

Stem cell treatment promotes repair and growth of damaged, dysfunctional, or diseased tissues through the utilization of stem cells. Through this, stem cell therapy is often referred to as regenerative medicine. When done right, stem cell treatment enables the repair and healing of damaged organs.

However, stem cell treatment is not a cure-all. They are more common when dealing with problems in the muscles and bone marrows, where stem cells can routinely and reliably repair damages. But in specific organs, such as the pancreas and heart, stem cells can only reproduce under special conditions and circumstances. Stem cells are not panaceas; specific systems benefit more than others.

The basic idea in stem cell therapy for pets is the same as for humans. But because there are fewer medical regulations with animals than with humans, this regenerative process is used more with pets.

Pet stem cell therapy takes cells from the fat, bone marrow, umbilical cord, or blood of your pet or another animal with the same species, then injects them into the damaged area. The cells then get to work on the damages and cause new, healthy cells to grow, which will turn into unadulterated, healthy tissue.

Stem cell surgery is not for every pet, though. It will not magically cure the illness of your pet, and worse, it may cause adverse side effects. It is not for every budget bracket, either. Sessions can cost upwards of thousands of dollars, however, if it is for your pet care then it is worth it. Inquire a veterinarian about stem cell treatments and ask many inquiries about the procedure for pets.

Inflammation is caused by the immune systems response to foreign organisms. It is the bodys attempt at protecting itself by signaling the immune system to heal damages and defend from invaders. It is the same with dogs; inflammation is caused by the acting up of the immune system and the secretions of the white blood cells.

Stem cell treatments can be used to suppress or cure inflammation. Numerous studies cite the importance of Mesenchymal stem cells (MSCs) to counteract immune response and suppress inflammation for both humans and dogs.

In some instances, however, the immune system of both humans and animals dont work the way they were intended to be. Sometimes, the bodys defense response triggers an inflammation, even when there is nothing to fight off. These autoimmune diseases treat tissues as under attack of foreign invaders, even when there is no infection. Because of this, the bodys tissues are harmed.

In Pet Stem Cell Therapy, Adult Mesenchymal stem cells can be injected into affected joints. MSCs release anti-inflammatory enzymes that help relieve pain.

After ligament, tendon, or cartilage damage, the natural healing response takes over. But normal healing often results in scar formation and inferior tissue that fails to copy the original function, composition, and structure of the damaged part.

Regenerative healing suppresses inflammatory cells, and certain studies show that with Pet Stem Cell Therapy, MSCs improve tissue strength levels when compared to the still intact tissue.

Skeletal and muscle injuries are very common and may result from a wide variety of causes and mechanisms such as strains, lacerations, wounds, or over-exhaustion, which also affect dogs.

The transplanting of stem cells into the damaged or aberrant tissue is a central tenet of tissue engineering and regenerative medicine. Presently, the majority of reports treating skeletal and muscle injuries are limited mainly to animal experiments, and they produced positive results.

Degenerative diseases in dogs, such as degenerative myelopathy (a progressive condition in the spinal cord) and degenerative joint disease can be helped by pet stem cell therapy.

Owners report an improvement in mobility and range during the first few days and weeks of the procedure. Studies also show evidence in slowing the progression and the possible reversion of these rare, neurological diseases.

Pet stem cell therapy is mainly safe for your dogs, as the cells are harvested directly from your pet. However, stem cell treatments are looked down upon as cancer treatment because of its risk of causing cancer to worsen or spread more rapidly. Other than rest and support, minimal care is required for dogs after the procedure. Entrust your pet to a veterinarian with ample training and experience in regenerative medicine.

These are just some of the benefits of pet stem cell therapy. They can be successfully be used in a variety of treatments. However, research is still limited and the exact extent of avantages and even disadvantages is unknown. Like all treatments, Pet stem cell therapy also has side effects and limitations, it is best to do complete research and talk to an experianced vet who can guide you in the right decision. They will be better able to provide you the ifs and dont about how stem cell treatments can help your dog and their condition.

Read Out More Article5 Smart Reasons to Buy Pet Insurance Policy Now10 Cutest Dogs on Instagram12 Fictional Animal Sidekicks We Always Wanted But Cant Have

Follow this link:
Pet Stem Cell Therapy: How It Can Be A Life Saver For Your ...

The investigational DART protein MGD013, which targetd PD-1 and LAG-3, showed encouraging activity as a single agent as well as in combination with margetuximab as treatment of multiple tumor types in the MDG013 dose-escalation phase 1 study.

In the findinigs presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, partial response was observed in 3 patients, including 1 patient with gastric cancer and 1 patient with mesothelioma, both of whom had prior PD-1 therapy, as well as 1 patient with triple-negative breast cancer (TNBC) who was on therapy for more than 5 months. Additionally, 18 patients had stable disease as best overall response for a disease control rate of 48.8%.

Further, preliminary results in patients with relapsed/refractory HER2-positive solid tumors treated with MGD013 and margetuximab in the combination cohort had an overall response rate of 42.9% (6/14).

The rationale for dual targeting of PD-1 and LAG-3 stems from the observation that checkpoint molecules are leveraged by tumors or antigen presenting cells to evade the immune system, explained Jason J. Luke, MD, FACP, in a presentation. PD-1 and LAG-3 receptors are expressed on exhausted T-cells and interact with corresponding ligands in the gate anti-tumor activity.

Synergy of anti-PD-1 and anti-LAG-3 has been observed in preclinical models, explained Luke who is an associate professor of medicine in the Division of Hematology/Oncology and the director of the Cancer Immunotherapeutics Center within the University of Pittsburg Medical Center Hillman Cancer Immunology and Immunotherapy Program.

MGD013 is an investigational bispecific DART molecule that engages PD-1 and LAG-3 with a single molecule, resulting in greater T-cell activation than either a monoclonal antibody alone.

The phase 1 trial open-label, dose escalation and cohort expansion study (NCT03219268) was designed to characterize the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and preliminary antitumor activity of MGD013 administered by IV infusion every 2 weeks. Another hypothesis investigators tested in the study was whether or not tumors can be made more responsive to PD-1 and LAG-3 intervention with the addition of an Fc-engineered monoclonal antibody, such as margetuximab.

In the initial dose-escalation cohort, patients were treated with MGD013 in a 3 + 3 design from 1 mg up to 1200 mg. Upon establishment of 600 mgs every 2 weeks as the recommended dose, monotherapy cohort expansions in ovarian, TNBC and nonsmall cell lung cancer (NSCLC), as well as multiple other tumor types including squamous cell carcinoma of the head and neck, small cell lung cancer, hepatocellular carcinoma, cholangiocarcinoma, cervical cancer, gastric/gastroesophageal junction carcinoma, and diffuse large B-cell lymphoma began enrolling patients.

In total, 53 patients participated in dose-escalation cohort; 205 patients participated in monotherapy cohort expansion; and 21 patients were treated in combination with margetuximab.

The 3 confirmed partial responses in the dose-escalation cohort each occurred at a different dose. The patient with TNBC had a response after treatment with a 10-mg dose; the patient with mesothelioma had a response with the 800-mg dose; and the patient with gastric cancer had a response with the 1200-mg dose.

The all-grade immune-related adverse events (AEs) of special interest observed in the dose-escalation cohort included rash (13.2%), hypothyroidism (11.3%), and immune-related hepatitis (3.8%). Grade 3 or higher AEs included immune-related hepatitis (3.8%), and 1 patient each reported respective cases of rash, pancreatitis, colitis, and adrenal insufficiency (1.9% each).

Youll note that broadly, [MGD013] was well tolerated with a manageable immune related adverse event profile and safety consistent with PD-1 or PD-L1 monotherapy in the treatment value setting, said Luke. Importantly, on-mechanism toxicities with immune-mediated hepatitis and lipase increase with radiographic evidence of pancreatitis were observed, though both resolved easily with steroids.

Anti-tumor activity was also observed in the MGD013 monotherapy cohort expansion across multiple tumor types including epithelial ovarian cancer (n = 23), TNBC (n = 23), and NSCLC, including both checkpoint inhibitor-nave (n = 14) and post PD-1 (n = 15). Confirmed partial response was observed in 2, 1, 2, and 0 patients, respectively. The overall response rates of both confirmed and unconfirmed partial responses were 8.7%, 4.3%, 21.4%, and 13.3%, respectively. Further, stable disease rates were 43.5%, 34.8%, 50.0%, and 53.3%.

The responses translated to a disease control rate of 52.2% in patients with epithelial ovarian cancer, 39.1% in patients with TNBC, 64.3% in patients with checkpoint inhibitor-nave NSCLC, and 53.3% in patients with NSCLC following PD-1 treatment.

Several cohorts are still ongoing, including a lymphoma cohort, Luke said. He cited a case from this cohort of a 27-year-old man with diffuse large B cell lymphoma who had progression of disease after chimeric antigen receptor (CAR) T-cell therapy who went on to receive 600-mg dose of MGD013. The patients pretreatment biopsy was noted for high expression of PD-1 and LAG-3 co-currently. Following the single dose of MGD013, the patient went on to be admitted on day 11 due to grade 2 cytokine release syndrome, but had a complete response on PET scanning at day 24 per Lugano criteria, Luke said. The patient went on to have allogeneic stem cell transplant and as of the presentation, was in remission 11 months post-MGD013 and 9 months post-transplant.

Given this early activity of MGD013 and these biomarker results, we are interested to more broadly analyze LAG-3 expression and more overall interferon expression as associated with treatment outcome, Luke said.

Reference

Luke JJ, Patel MR, Hamilton EP, et al. A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD1 and LAG3, in patients with unresectable or metastatic neoplasms. J Clin Oncol. 2020;38(suppl 15; abstr 3004). doi:10.1200/JCO.2020.38.15_suppl.3004

See the rest here:
Encouraging Activity Observed With MGD013 In Various Tumor Types - Targeted Oncology

A synopsis of the global canine stem cell therapy market with reference to the global healthcare pharmaceutical industry

Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.

Parent Indicators Healthcare Current expenditure on health, % of gross domestic product Current expenditure on health, per capita, US$ purchasing power parities (current prices, current PPPs) Annual growth rate of current expenditure on health, per capita, in real terms Out-of-pocket expenditure, % of current expenditure on health Out-of-pocket expenditure, per capita, US$ purchasing power parity (current prices, current PPPs) Physicians, Density per 1000 population (head counts) Nurses, Density per 1000 population (head counts) Total hospital beds, per 1000 population Curative (acute) care beds, per 1000 population Medical technology, Magnetic Resonance Imaging units, total, per million population Medical technology, Computed Tomography scanners, total, per million population

Research Methodology

Get Sample Copy of this report at https://www.xploremr.com/connectus/sample/2360

XploreMR utilizes a triangulation methodology that is primarily based on experimental techniques such as patient-level data, to obtain precise market estimations and insights on Molecule and Drug Classes, API Formulations and preferred modes of administration. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.

Secondary research is used at the initial phase to identify the age specific disease epidemiology, diagnosis rate and treatment pattern, as per disease indications. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, nursing managers, clinical specialists who provide valuable insights on trends and clinical application of the drugs, key treatment patterns, adoption rate, and compliance rate.

Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level.

On the other hand, we also analyse various companies annual reports, investor presentations, SEC filings, 10k reports and press release operating in this market segment to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at Tier level based on their revenues, product portfolio and presence.

Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as per capita healthcare expenditure, disposable income, industry based demand driving factors impacting the market and its forecast trends apart from disease related factors.

Browse Full Report at https://www.xploremr.com/report/2360/canine-stem-cell-therapy-market

Standard Report Structure Executive Summary Market Definition Macro-economic analysis Parent Market Analysis Market Overview Forecast Factors Segmental Analysis and Forecast Regional Analysis Competition Analysis

Target Audience Production Companies Suppliers Channel Partners Marketing Authorities Subject Matter Experts Research Institutions Financial Institutions Market Consultants Government Authorities

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type: Allogeneic Stem Cells Autologous Stem cells

Application: Arthritis Dysplasia Tendonitis Lameness Others

End User: Veterinary Hospitals Veterinary Clinics Veterinary Research Institutes

Region: North America Latin America Europe Asia Pacific Japan Middle East & Africa

Buy Full Report at https://www.xploremr.com/cart/2360/SL

About Us

XploreMR is one of the worlds leading resellers of high-quality market research reports. We feature in-depth reports from some of the worlds most reputed market research companies and international organizations. We serve across a broad spectrum from Fortune 500 to small and medium businesses. Our clients trust us for our unwavering focus onquality and affordability. We believe high price should not be a bottleneck for organizations looking to gain access to quality information.

Contact us:XploreMR111 North Market Street, Suite 300,San Jose, CA 95113, United StatesPh.No: +16692840108

Here is the original post:
Canine Stem Cell Therapy Market Will Make a Huge Impact in Near Future - Cole of Duty

A recent report published by QMI on brain tumor diagnosis and treatments market is a detailed assessment of the most important market dynamics. After carrying out thorough research on the market of brain tumor diagnosis and treatments historical as well as current growth parameters, business expectations for growth are obtained with utmost precision. The study identifies specific and important factors affecting the market for brain tumor diagnosis and treatments during the forecast period. It can enable manufacturers of brain tumor diagnosis and treatments to change their production and marketing strategies in order to envisage maximum growth. The market report on brain tumor diagnosis and treatments offers detailed information for stakeholders in the most comprehensive way on the current and future growth prospects of the demand for brain tumor diagnosis and treatments market.

To Request Sample Premium Reports: https://www.quincemarketinsights.com/request-sample-60808?utm_source=SSK&utm_medium=AS&utm_campaign=SSK

This report provides comprehensive taxonomy and the description of industry-related products, applications and end-user channels for the brain tumor diagnosis and treatments market. This report also provides insight into market concepts for phase. This contains opportunity analysis which provides information on the most relevant macroeconomic and microeconomic factors affecting market revenues and estimates for the phase. The market background is discussed in the report which sheds a light on the key drivers, threats, patterns and opportunities in the demand for brain tumor diagnosis and treatments market. A global overview has been presented for brain tumor diagnosis and treatments products, supply chain analysis and hazard analysis, which is expected to help readers identify the key factors that support the growth of the demand for brain tumor diagnosis and treatments market. The report discusses the regulatory scenario affecting approvals for the products, across leading regions. It also provides information on the demand of the brain tumor diagnosis and treatments market adopted in leading countries. It includes a specific list of retailers and manufacturers dealing in brain tumor diagnosis and treatments market. Readers will also be able to find regional developments and regulations that impact market growth. Significant growth prospects are given for countries which also include key regional developments and factors that influence the growth of the demand for brain tumor diagnosis and treatments market. The report studies business patterns of top companys like- fujifilm holdings corporation, analogic corporation, siemens healthcare, esaote s.p.a, toshiba medical systems corporation, ge healthcare, philips healthcare, hitachi medical corporation, and mindray medical international ltd

Get TOC For The Overview Of The Premium Report: https://www.quincemarketinsights.com/request-toc-60808?utm_source=SSK&utm_medium=AS&utm_campaign=SSK

Brain tumor diagnosis and treatments market growth is expected to gain high momentum during the forecast period due to increasing demand for imaging devices for diagnostics applications. An ceiling-mounted surgical lights is a medical imaging device, which uses high-frequency waves to visualize the internal organs of the body such as blood vessels, kidney, liver, human foetus, heart, etc. This market is gaining momentum, owing to the increase in the number of hospitals and adoption of technologically advanced devices, which can serve the purpose for both diagnostics and therapeutics. Moreover, the cumulative prevalence of cancer is driving the demand for early detections and minimization of expenses. According to the Cancer Research Institute (CRI), there were approximately 17 million new cases of cancer globally, as of 2017, which is also fuelling the demand for ultrasound devices.

Segment Analysis

The bed head multifunctional belt market has been segmented into product type, device display, portability, and application. Based on product type, the market has been divided into diagnostic and therapeutic. The diagnostic product type segment can be further divided into 2D ultrasound, 3D/4D ultrasound, and Doppler ultrasound. The therapeutic segment can be further divided into shockwave lithotripsy and focused ultrasound. The growth of the bed head multifunctional belt market can be attributed to its advanced technology and increased efficacy.

Based on the device display, the market can be segmented into colour ultrasound and black/white ultrasound. Based on portability, the market can be divided into trolley/cart and compact/handheld. Based on application, the market has been divided into radiology, gynaecology, urology, cardiology, orthopaedic/musculoskeletal, and others. Owing to the growing incidences of stem cell-based injuries and the demand for high-quality diagnostic procedures, the radiology segment is expected to lead. The market has been studied for North America, Western Europe, Eastern Europe, Asia Pacific, and Rest of the World.

Key Factors Impacting Market Growth:

Regional Outlook:

North America, Western Europe, and Asia Pacific by region are estimated to dominate the ultrasound market during the forecast period. These regions have been market leaders for the overall healthcare sector in terms of technological developments and advanced medical treatments. Moreover, the government policies have been favourable for the growth of the healthcare infrastructure in these regions. North America and Western Europe have an established healthcare infrastructure for product innovations and early adaptations. This is expected to drive the demand for ultrasound market during the forecast period.

The US, Germany, France, UK, Canada, and Spain have been some the major markets in the region. Asia Pacific is estimated to register one of highest CAGR for ultrasound market during the forecast period. This region has witnessed strategic investments by global companies to cater the growing demand in the recent years. China, Japan, India, South Korea, and Australia are amongst some of the key countries for ultrasound market in the region. Other regions including Middle East, Eastern Europe, and Rest of the World (South America and Africa) are estimated to be emerging markets for ultrasound during the forecast period.

Speak To Analyst before Buying This: https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-60808?utm_source=SSK&utm_medium=AS&utm_campaign=SSK

Companies Covered: Beck Technology, Ltd., Autodesk, Inc., Dassault Systemes SA, Trimble Navigation Ltd, Synchro Software Ltd, Pentagon Solutions Ltd, Bentley Systems.

Market Segmentation:

By Product Type: Primary Brain Tumor Meningioma Gliomas Astrocytomas Pituitary Tumors) Secondary Brain TumorBy Diagnosis Type: CT Scan MRI PET-CT Scan Molecular Testing EEGBy Treatment Type: Surgery Radiation Therapy Targeted Therapy Chemotherapy Immunotherapy

By Region: North America North America, by Country US Canada Mexico North America, by Product Type North America, by Diagnosis Type North America, by Treatment Type Western Europe Western Europe, by Country Germany UK France Italy Spain The Netherlands Rest of Western Europe Western Europe, by Product Type Western Europe, by Diagnosis Type Western Europe, by Treatment Type Asia Pacific Asia Pacific, by Country China India Japan South Korea Australia Indonesia Rest of Asia Pacific Asia Pacific, by Product Type Asia Pacific, by Diagnosis Type Asia Pacific, by Treatment Type Eastern Europe Eastern Europe, by Country Russia Turkey Rest of Eastern Europe Eastern Europe, by Product Type Eastern Europe, by Diagnosis Type Eastern Europe, by Treatment Type Middle East Middle East, by Country UAE Saudi Arabia Qatar Iran Rest of Middle East Middle East, by Product Type Middle East, by Diagnosis Type Middle East, by Treatment Type Rest of the World Rest of the World, by Country South America Africa Rest of the World, by Product Type Rest of the World, by Diagnosis Type Rest of the World, by Treatment Type

Reasons to Buy This Report:

Customization:

We provide customization of the study to meet specific requirements:

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109

Pune, Maharashtra 411028

Phone: US +1 208 405 2835 / UK +44 121 364 6144 / APAC +91 706 672 4848

Email: sales@quincemarketinsights.com

Web: http://www.quincemarketinsights.com

Read the original post:
Brain Tumor Diagnosis And Treatments Market Report Analysis & Forecast 2028 - Azizsalon News

The recently published market study by MRRSE highlights the current trends that are expected to influence the dynamics of the Canine Stem Cell Therapy market in the upcoming years. The report introspects the supply chain, cost structure, and recent developments pertaining to the Canine Stem Cell Therapy market in the report and the impact of the COVID-19 on these facets of the market. Further, the micro and macro-economic factors that are likely to impact the growth of the Canine Stem Cell Therapy market are thoroughly studied in the presented market study.

According to the report, the Canine Stem Cell Therapy market is expected to grow at a CAGR of ~XX% during the forecast period, 20XX-20XX and attain a value of ~US$ XX by the end of 20XX. The report is a valuable source of information for investors, stakeholders, established and current market players who are vying to improve their footprint in the current Canine Stem Cell Therapy market landscape amidst the global pandemic.

Request Sample Report @https://www.mrrse.com/sample/16152?source=atm

Reasons to Trust Our Business Insights

Critical Data in the Canine Stem Cell Therapy Market Report

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/16152?source=atm

Regional Assessment

The regional assessment chapter in the report offers an out and out understanding of the potential growth of the Canine Stem Cell Therapy market across various geographies such as:

Application Assessment

The presented study ponders over the numerous applications of the Canine Stem Cell Therapy and offers a fair assessment of the supply-demand ratio of each application including:

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type:

Application:

End User:

Region:

Buy This Report @ https://www.mrrse.com/checkout/16152?source=atm

The report resolves the following doubts related to the Canine Stem Cell Therapy market:

Read the rest here:
How Coronavirus is Impacting Market Research on Canine Stem Cell Therapy Market 2019 and Analysis to 2028 - News Distinct

New York City, United States Since the COVID-19 infection flare-up in December 2019, the malady has spread to right around 100 nations around the world with the World Health Organization proclaiming it a general wellbeing crisis. The worldwide effects of the coronavirus sickness 2019 (COVID-19) are now beginning to be felt, and will essentially influence the Healthcare Industry in 2020.

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade.

Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/15550

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/15550

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field.

The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness a CAGR of 4.2% during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation of US$ 218.2 Mn by the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs.

A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment.

However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/15550

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians.

A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Pressure Guidewires MarketPressure Guidewire Market Segmented By Flat Tipped Pressure Guidewires, Flexible Tipped Pressure Guidewires Product with Pressure Wire Technology, Optical Fiber Technology Type for Hospitals, Ambulatory Surgical Centers, Independent Catheterization Labs.For More Information

Compression Therapy Devices MarketThe compression therapy market of North America is projected to escalate from US$ 2,377.8 Mn in 2014 to US$ 1,515.4 Mn, registering a CAGR of 5.4% by 2020-end.For More Information

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Salessales@persistencemarketresearch.comWebsitehttps://www.persistencemarketresearch.com

Continue reading here:
Canine Stem Cell Therapy Market Covid-19 Impact In 2026 | In-depth Analysis, Global Market Share, Top Trends, Professional & Technical Industry...